Previous reports on lung, colon, and breast cancers have demonstrated that LRFN4’s ability to enhance cell proliferation, invasion, and chemotherapy resistance, suggesting its involvement in multiple oncogenic pathways (43, 44). This evidence concerns the gene LRFN4 and breast cancer.